Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 8/20 | 0.83 |
| ▸ | KIT | P10721 | 5/20 | 0.80 |
| ▸ | CSF1R | P07333 | 4/20 | 0.80 |
| ▸ | BRAF | P15056 | 4/20 | 0.78 |
| ▸ | EGFR | P00533 | 3/20 | 0.78 |
| ▸ | ABL1 | P00519 | 4/20 | 0.76 |
| ▸ | LYN | P07948 | 1/20 | 0.72 |
| ▸ | BCR | P11274 | 1/20 | 0.72 |
| ▸ | KIF5B | P33176 | 1/20 | 0.69 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13772031 | 0.92 | BRAF (0.79) | RETKITCSF1RBRAFEGFR | |
| SCHEMBL13772003 | 0.91 | RET (0.70) | RETKITCSF1RBRAFEGFR | |
| SCHEMBL13772005 | 0.89 | BRAF (0.69) | RETKITCSF1RBRAFEGFR | |
| SCHEMBL4906580 | 0.88 | CSF1R (0.72) | RETKITCSF1RBRAFEGFR | |
| SCHEMBL28806373 | 0.88 | BRAF (0.75) | RETKITCSF1RBRAFEGFR | |
| SCHEMBL13772100 | 0.87 | RET (0.66) | RETKITCSF1RBRAFEGFR | |
| SCHEMBL12397825 | 0.87 | ABL1 (0.81) | KITCSF1RABL1BCR | |
| SCHEMBL30616136 | 0.87 | BRAF (0.84) | RETKITCSF1RBRAFEGFR | |
| SCHEMBL13772103 | 0.87 | RET (0.65) | RETKITCSF1RBRAFEGFR | |
| SCHEMBL31620832 | 0.86 | BRAF (0.69) | RETKITCSF1RBRAFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018046-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | RET 4873/4885KIT 3086/4885CSF1R 3269/4885 |
| US-20130018046-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | RET 4873/4885KIT 3086/4885CSF1R 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.